Objective To study the epidemiological and clinical features of children with coronavirus disease 2019 (COVID-19) caused by Delta variant infection and their differences from children with ordinary COVID-19 (non-Delta variant infection). Methods Eleven children aged <14 years, who were diagnosed with COVID-19 caused by Delta variant infection from August to September 2021 were enrolled (variant group). Five children aged <14 years who were diagnosed with ordinary COVID-19 from February to March 2020 served as the control group. The epidemiological data, clinical features, and laboratory examination results were compared between the two groups. Results There was no significant difference in the proportion of children with clinical symptoms between the two groups (P>0.05). There were no significant differences in white blood cell count, lymphocyte count, and platelet count between the two groups (P>0.05), while the variant group had a lower neutrophil count than the control group (P<0.05). Lymphocytopenia was not observed in either group. Compared with the control group, the variant group had a higher proportion of children with an increase in creatine kinase isoenzyme (P<0.05), while there were no significant differences in the proportion of children with an increase in lactate dehydrogenase, D-Dimer, C-reactive protein or interleukin-6 between the two groups (P>0.05). Among the 9 children in the variant group, 5 tested positive for IgM antibody at week 2 after admission, and all children tested positive for IgG antibody. At week 3 after admission, the level of IgM antibody tended to decrease in 9 children, and the level of IgG antibody tended to decrease in 8 children. Conclusions Delta variant is more infectious. COVID-19 caused by Delta variant infection may cause more serious myocardial damage than ordinary COVID-19 in children. In children infected with Delta variant, IgG antibody appears at almost the same time as IgM antibody.
Key words
COVID-19 /
Delta variant /
Clinical feature /
Child
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
References
1 Yang Y, Lu QB, Liu MJ, et al. Epidemiological and clinical features of the 2019 novel coronavirus outbreak in China[J]. medRxiv, 2020. DOI: 10.1101/2020.02.10.20021675.
2 Munster VJ, Koopmans M, van Doremalen N, et al. A novel coronavirus emerging in China—key questions for impact assessment[J]. N Engl J Med, 2020, 382(8): 692-694. PMID: 31978293. DOI: 10.1056/NEJMp2000929.
3 中华人民共和国国家卫生健康委员会. 新型冠状病毒肺炎诊疗方案(试行第八版修订版)[J]. 中华临床感染病杂志, 2021, 14(2): 81-88. DOI: 10.3760/cma.j.issn.1674-2397.2021.02.001.
4 Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory disease in China[J]. Nature, 2020, 579(7798): 265-269. PMID: 32015508. PMCID: PMC7094943. DOI: 10.1038/s41586-020-2008-3.
5 PANGO Lineages. Latest epidemiological lineages of SARS-CoV-2[EB/OL]. [2021-07-16].https://cov-lineages.org/global_report.html.
6 Outbreak.info. B.1.617.2 lineage report[EB/OL]. [2021-07-27]. https://outbreak.info/situation-reports?pango=B.1.617.2.
7 Di Giacomo S, Mercatelli D, Rakhimov A, et al. Preliminary report on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike mutation T478K[J]. J Med Virol, 2021, 93(9): 5638-5643. PMID: 33951211. PMCID: PMC8242375. DOI: 10.1002/jmv.27062.
8 Chan JFW, Yuan SF, Kok KH, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster[J]. Lancet, 2020, 395(10223): 514-523. PMID: 31986261. PMCID: PMC7159286. DOI: 10.1016/S0140-6736(20)30154-9.
9 Huang CL, Wang YM, Li XW, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China[J]. Lancet, 2020, 395(10223): 497-506. PMID: 31986264. PMCID: PMC7159299. DOI: 10.1016/S0140-6736(20)30183-5.
10 Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China[J]. N Engl J Med, 2020, 382(18): 1708-1720. PMID: 32109013. PMCID: PMC7092819. DOI: 10.1056/NEJMoa2002032.
11 师晓东, 罗丹青. 儿童中性粒细胞减少症的最新分类与治疗进展[J]. 中华实用儿科临床杂志, 2018, 33(3): 173-176. DOI: 10.3760/cma.j.issn.2095-428X.2018.03.004.
12 代艳, 唐宁宁, 徐帆, 等. 广西儿童新型冠状病毒肺炎11例临床分析[J]. 中国临床新医学, 2020, 13(11): 1149-1152. DOI: 10.3969/j.issn.1674-3806.2020.11.18.
13 McCallum M, Bassi J, Marco AD, et al. SARS-CoV-2 immune evasion by variant B.1.427/B.1.429[J]. bioRxiv, 2021. PMID: 33821281. PMCID: PMC8020983. DOI: 10.1101/2021.03.31.437925. Epub ahead of print.
14 Guo L, Ren LL, Yang SY, et al. Profiling early humoral response to diagnose novel coronavirus disease (COVID-19)[J]. Clin Infect Dis, 2020, 71(15): 778-785. PMID: 32198501. PMCID: PMC7184472. DOI: 10.1093/cid/ciaa310.
15 Lou B, Li TD, Zheng SF, et al. Serology characteristics of SARS-CoV-2 infection after exposure and post-symptom onset[J]. Eur Respir J, 2020, 56(2): 2000763. PMID: 32430429. PMCID: PMC7401320. DOI: 10.1183/13993003.00763-2020.
16 Zhao JJ, Yuan Q, Wang HY, et al. Antibody responses to SARS-CoV-2 in patients with novel coronavirus disease 2019[J]. Clin Infect Dis, 2020, 71(16): 2027-2034. PMID: 32221519. PMCID: PMC7184337. DOI: 10.1093/cid/ciaa344.
17 罗效梅, 王静, 张娅, 等. 全血SARS-CoV-2特异性抗体检测对2019-冠状病毒病的临床应用价值分析[J]. 西南大学学报(自然科学版), 2020, 42(3): 30-34. DOI: 10.13718/j.cnki.xdzk.2020.03.005.
PDF(543 KB)
